Suez Canal Univ. VEGFR2 compound 17

Suez Canal Univ. VEGFR2 compound 17: sourced facts only. name: "Interestingly, among the identified lead molecules, compound 17 displayed remarkable VEGFR2 inhibition activity with IC50 value of 19.8 nM compared to Sunitinib (IC50 = 75 nM) and Sorafenib (IC50 = 30 nM)." [PMID:35290929]; target: "Interestingly, among the identified lead molecules, compound 17 displayed remarkable VEGFR2 inhibition activity with IC50 value of 19.8 nM compared to Sunitinib (IC50 = 75 nM) and Sorafenib (IC50 = 30 nM)." [PMID:35290929]; developer: "Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt. Electronic address: [email protected]." [PMID:35290929]; stage: "Additionally, in vivo (Xenograft model) study validated the anticancer activity of the hit compound 17, which showed a tumor inhibition ratio of 54.2 % compared to 5-FU (49.5%) with an improvement of hematological and biochemical parameters." [PMID:35290929]